Heat Shock Protein 70 (Hsp70) Peptide Activated Natural Killer (NK) Cells for the Treatment of Patients with Non-Small Cell Lung Cancer (NSCLC) after Radiochemotherapy (RCTx) – From Preclinical Studies to a Clinical Phase II Trial by Hanno M. Specht et al.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
REVIEW ARTICLE
published: 15 April 2015
doi: 10.3389/fimmu.2015.00162
Heat shock protein 70 (Hsp70) peptide activated Natural
Killer (NK) cells for the treatment of patients with non-small
cell lung cancer (NSCLC) after radiochemotherapy (RCTx) –
from preclinical studies to a clinical phase II trial
Hanno M. Specht 1, Norbert Ahrens2, Christiane Blankenstein3,Thomas Duell 4, Rainer Fietkau5,
Udo S. Gaipl 5, Christine Günther 6, Sophie Gunther 1, Gregor Habl 1, Hubert Hautmann7,
Matthias Hautmann8, Rudolf Maria Huber 9, Michael Molls1, Robert Offner 2, Claus Rödel 10, Franz Rödel 10,
Martin Schütz 11, Stephanie E. Combs1 and Gabriele Multhoff 1,12*
1 Radiation Oncology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany
2 Transfusion Medicine, Institute for Clinical Chemistry and Laboratory Medicine, University Hospital Regensburg, Regensburg, Germany
3 Münchner Studienzentrum (MSZ), Klinikum rechts der Isar, Technische Universität München, Munich, Germany
4 Thoracic Oncology, Asklepios Lungenfachkliniken, Munich, Germany
5 Radiation Oncology, University Hospital Erlangen, Erlangen, Germany
6 GMP Laboratory, apceth GmbH & Co. KG, Munich, Germany
7 Thoracic Oncology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany
8 Radiation Oncology, University Hospital Regensburg, Regensburg, Germany
9 Thoracic Oncology, Department of Medicine, University of Munich, Munich, Germany
10 Radiation Oncology, University Hospital Frankfurt, Frankfurt, Germany
11 Thoracic Oncology, Klinikum Bogenhausen, Munich, Germany
12 Institute of Biological Molecular Imaging, Helmholtz Zentrum München, Munich, Germany
Edited by:
Francisco Borrego, BioCruces Health
Research Institute, Spain
Reviewed by:
Roland Jacobs, Hannover Medical
University, Germany
Olatz Zenarruzabeitia, BioCruces
Health Research Institute, Spain
*Correspondence:
Gabriele Multhoff , Experimental
Radiation Oncology, Klinikum rechts
der Isar, Technische Universität
München (TU München), Ismaninger
Str. 22, Munich 81675, Germany
e-mail: gabriele.multhoff@lrz.
tu-muenchen.de
Heat shock protein 70 (Hsp70) is frequently overexpressed in tumor cells. An unusual
cell surface localization could be demonstrated on a large variety of solid tumors includ-
ing lung, colorectal, breast, squamous cell carcinomas of the head and neck, prostate
and pancreatic carcinomas, glioblastomas, sarcomas and hematological malignancies, but
not on corresponding normal tissues. A membrane (m)Hsp70-positive phenotype can be
determined either directly on single cell suspensions of tumor biopsies by flow cytom-
etry using cmHsp70.1 monoclonal antibody or indirectly in the serum of patients using
a novel lipHsp70 ELISA. A mHsp70-positive tumor phenotype has been associated with
highly aggressive tumors, causing invasion and metastases and resistance to cell death.
However, natural killer (NK), but not T cells were found to kill mHsp70-positive tumor cells
after activation with a naturally occurring Hsp70 peptide (TKD) plus low dose IL-2 (TKD/IL-2).
Safety and tolerability of ex vivoTKD/IL-2 stimulated, autologous NK cells has been demon-
strated in patients with metastasized colorectal and non-small cell lung cancer (NSCLC) in
a phase I clinical trial. Based on promising clinical results of the previous study, a phase
II randomized clinical study was initiated in 2014. The primary objective of this multicen-
ter proof-of-concept trial is to examine whether an adjuvant treatment of NSCLC patients
after platinum-based radiochemotherapy (RCTx) with TKD/IL-2 activated, autologous NK
cells is clinically effective. As a mHsp70-positive tumor phenotype is associated with poor
clinical outcome only mHsp70-positive tumor patients will be recruited into the trial. The
primary endpoint of this study will be the comparison of the progression-free survival of
patients treated with ex vivo activated NK cells compared to patients who were treated with
RCTx alone. As secondary endpoints overall survival, toxicity, quality-of-life, and biological
responses will be determined in both study groups.
Keywords: Hsp70-based immunotherapy, NSCLC patients, radiochemotherapy clinical trial, clinical phase II, NK cells
INTRODUCTION
The major stress-inducible heat shock protein 70 (Hsp70) is
known as a cytoprotective molecular chaperone, which is fre-
quently overexpressed in a large variety of tumor cells. As a molec-
ular chaperone Hsp70 supports the correct folding of nascent and
misfolded proteins, prevents protein aggregation following stress
and assists protein transport across membranes (1). High cytoso-
lic Hsp70 levels in tumor cells are associated with poor prognosis,
metastatic spread (2) and resistance to standard therapies, such
as radiochemotherapy (RCTx) (3–7). Inside tumor cells Hsp70
contributes to tumor cell survival by interfering with apoptosis
pathways (8, 9).
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Apart from these intracellular chaperoning functions Hsp70
has been found to be expressed on the cell surface of highly
aggressive primary and metastatic tumor cells. This finding was
not expected since Hsp70 lacks a transmembrane domain. Ini-
tially, the membrane expression of Hsp70 was proven by selective
cell surface iodination (10) and by biotinylation followed by pro-
teomic profiling of cell surface bound proteins (11). Later a mouse
monoclonal antibody was established [cmHsp70.1 mAb; (12)],
which is able to detect mHsp70 highly selectively on the plasma
membrane of viable tumor cells by flow cytometry. Screening of
viable single cell suspensions of more than 1,000 freshly isolated
tumor biopsies and their corresponding normal tissues revealed
that more than 50% of all tumors, but none of the healthy normal
tissues exhibited a mHsp70-positive phenotype (13, 14). A prog-
nostic value of mHsp70 on tumor cells has been demonstrated in
xenograft tumor mouse models (13), since metastases of ortho-
topically implanted primary tumor cells showed a significantly
higher surface Hsp70 density than the primary tumor cells (15).
Moreover, survival of patients with mHsp70-positive squamous
cell carcinoma of the lung and lower rectal carcinomas revealed
a significantly decreased overall survival (OS) (16) compared to
their mHsp70-negative counterparts.
Evidence is accumulating that cell surface translocation of
Hsp70 in tumor cells is mediated via non-classical vesicular path-
ways (17) since inhibitors of the classical ER-Golgi transport route
(Brefeldin A, Monensin) did not affect the cell surface expression
of Hsp70. Anchorage of Hsp70 in the plasma membrane of tumor
cells is most likely enabled by tumor-specific lipid components,
such as globotriaosylceramide Gb3 (18), which directly interact
with Hsp70 and are compounds of lipid rafts. Whether mHsp70
in lipid rafts mediates chaperone activity for cell surface signaling
receptors is still a matter of debate. Following stress, such as a non-
lethal radio- or chemotherapy not only the intracellular Hsp70
levels but also the membrane density of Hsp70 was found to be
increased in tumor cells (19–21). Following irradiation Hsp70 is
predominantly co-located with phosphatidylserine in the plasma
membrane of tumor cells and thus has to leave the cholesterol-rich
microdomain signaling platforms (22). Although elevated Hsp70
membrane and cytosolic levels confer resistance of tumor cells to
standard therapies such as radio- and chemotherapy (2, 5, 6, 8),
it also has been shown that mHsp70 serves as a target structure
for activated natural killer (NK) cells. It appears that mHsp70 can
fulfill dual functions: on the one hand, it can mediate protection
against lethal damage, which is induced by radio- and chemother-
apy; on the other hand, it might provide a target structure for the
cytolytic attack by the innate immune system (13, 14, 16, 19).
PRECLINICAL FINDINGS
ACTIVATION OF NK CELLS WITH Hsp70 PEPTIDE TKD PLUS IL-2 AND
IDENTIFICATION OF CD94 AS A SURROGATE MARKER FOR CYTOLYTIC
ACTIVE NK CELLS
Previously, we demonstrated that incubation of NK, but not T
cells, with peptide-free recombinant Hsp70 protein in combina-
tion with pro-inflammatory cytokines, such as IL-2 or Il-15 can
stimulate the cytotoxic, proliferative, and migratory capacity of
NK cells against highly aggressive, mHsp70-positive tumor cells,
in vitro (14, 23). Similar to full-length Hsp70 protein, a 14-mer
peptide (TKDNNLLGRFELSG, aa 450–463) also could activate
the cytolytic and proliferative capacity of NK cells at equimolar
concentrations (24). The stimulatory 14-mer peptide is an N-
terminal extension of the 8-mer binding epitope of the antibody
cmHsp70.1, which detects mHsp70 on the cell surface of tumor
cells. Since the induction of the cytolytic activity of NK cells with
the peptide is dose-dependent and saturable it is assumed that
the interaction of NK cells with the peptide might be receptor-
mediated. By antibody and protein/peptide blocking assays the
C-type lectin receptor CD94 could be identified as a potential
receptor, which mediates the interaction with the stimulatory
Hsp70 peptide. CD94 forms a heterodimer either with the co-
receptor NKG2A or NKG2C and thus acts as an inhibitory or
activation receptor complex. Following incubation of NK cells
with Hsp70 protein or Hsp70 peptide plus IL-2, the density of
CD94 was found to be significantly up-regulated concomitant with
an increased cytolytic activity against mHsp70-positive tumor cells
(25, 26). Therefore, the density of CD94 on NK cells was consid-
ered as a surrogate marker for the cytolytic activity of NK cells
against mHsp70-positive tumor cells.
MODE OF TUMOR CELL KILLING OF mHsp70-POSITIVE TUMOR CELLS BY
PEPTIDE PLUS IL-2 ACTIVATED NK CELLS
It has been shown that cell membrane-bound Hsp70 renders
tumor cells more susceptible to the lysis of NK cells that had
been stimulated with Hsp70 protein/peptide plus low dose IL-
2 (13, 14). In order to uncover the mechanism of lysis affin-
ity chromatography, experiments were performed using lysates
of activated NK cells on columns that were bound to either
Hsp70 protein or Hsp70 peptide. Interestingly, the apoptosis-
inducing serine protease granzyme B has been found to show
an interaction with Hsp70 protein and peptide as determined by
matrix-laser desorption ionization time of flight mass peptide fin-
ger printing (MALDI-TOF) (27). The interaction of granzyme B
with Hsp70 was previously confirmed by Western blot and flow
cytometry (27).
Natural killer cells that have been stimulated with Hsp70 plus
IL-2 show a significantly up-regulated production of granzyme
B in their intracellular vesicles. In contrast, the levels of perforin
were found to be up-regulated only moderately (25, 26). Therefore,
it is assumed that mHsp70-positive tumor cells are predomi-
nantly killed by granzyme B. Incubation of isogenic tumor cell
systems that differ in their mHsp70 expression levels indicate that
granzyme B in the absence of perforin effectively lysed mHsp70-
positive tumor cells, but not their mHsp70-negative counterparts.
Regarding these results, we concluded that Hsp70-positive tumor
cells are killed by Hsp70 plus IL-2 activated, CD94-positive NK
cells via granzyme B-mediated apoptosis (27).
PRECLINICAL MODELS SHOWING THE EFFICACY OF Hsp70 PLUS IL-2
ACTIVATED NK CELLS
An incubation of purified human NK cells with Hsp70 peptide
plus low dose IL-2 resulted in a specific tumor cell killing of
mHsp70-positive, but not their mHsp70-negative counterparts,
in vitro. Furthermore, activated NK cells compared to resting
NK cells showed a significantly increased migratory capacity
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toward mHsp70-positive tumor cells as demonstrated in a tran-
swell migration system. In order to proof the Hsp70-based anti-
tumor activity of NK cells, in vivo immunodeficient SCID/beige
mice bearing Hsp70-positive colon carcinoma cells were injected
intravenous (i.v.) into the tail vein with either peripheral blood
lymphocytes (PBLs), CD3-positively sorted T lymphocytes or
CD3-negative CD94-positive NK cells that had been stimulated ex
vivo with Hsp70 peptide plus low dose IL-2. A single injection of
activated NK, but not of T cells, was found to result in a significant
reduction in the tumor weight of the mice (28). After stimulation
of PBL with Hsp70 peptide plus IL-2 activation markers such as
CD25 or CD69 were found to be increased predominantly on the
NK cell fraction. This result indicated that it is possible to selec-
tively stimulate NK cells within unsorted PBL. Furthermore, the
amount of tumor cell killing appeared to correlate with the actual
number of activated NK cells that show a high expression density
of CD94 (25, 26).
Ex vivo activated human NK cells could also control metasta-
sized mHsp70-positive pancreatic carcinomas in immunodeficient
mice, as shown previously (15). These data indicate that mHsp70
acts as a universal tumor-specific target structure, which is not
restricted to only one specific tumor entity. In contrast, unstimu-
lated NK cells did not induce tumor cell killing. Interestingly, NK
cells that had been stimulated with IL-2 only were significantly
less efficient in the control of the tumor growth in mice. A sin-
gle injection of mice with Hsp70 peptide plus IL-2 activated NK
cells, but not with identically stimulated T cells or IL-2 activated
NK cells was also able to significantly enhance the OS of tumor-
bearing mice (15). Following four repeated i.v. injections with
Hsp70 peptide plus IL-2 pre-activated NK cells, the primary pan-
creatic tumor was found to be eliminated completely and hepatic
metastases could be prevented (15).
CLINICAL RESULTS
SUMMARY OF THE FINDINGS OF A PHASE I CLINICAL TRIAL USING
Hsp70 PEPTIDE PLUS IL-2 ACTIVATED NK CELLS
Based on promising preclinical results using ex vivo activated NK
cells in different tumor mouse models, a phase I clinical trial in
tumor patients was performed in 2002 (29). Mouse models also
have indicated that pre-activated NK cells are well tolerated even at
high numbers (28). A major goal of the previously performed clin-
ical phase I study (29) was to test whether a treatment of tumor
patients with autologous, ex vivo Hsp70 peptide plus IL-2 acti-
vated NK cells is safe and well tolerated. After i.v. injection of
escalating numbers of ex vivo pre-activated NK cells and escalat-
ing numbers of treatment cycles (up to six cycles) using complete
leukapheresis products none of the patients showed any severe
toxicities [no toxicities ≥grade 2 according to common toxicity
criteria (CTC)]. Biological and clinical responses were evaluated in
patients with confirmed metastatic colorectal cancer (N = 11) and
non-small cell lung cancer (NSCLC) (N = 1) who failed clinical
responses to standard therapies such as chemotherapy, radiother-
apy, or laser-induced thermotherapy. At the beginning of the NK
cell-based therapy, patients suffered from multiple pulmonary,
hepatic, soft tissue and bone metastases, or local relapses. Because
of the advanced tumor stages of the patients, it was ethically not
accepted to obtain fresh biopsies to determine the Hsp70 status
of the tumor during the study. Patients were enrolled in the study
at least 4 weeks after the last standard therapy. Leukocyte concen-
trates were obtained from all patients by a 3–4 h leukapheresis
at the Institute for Clinical Chemistry and Laboratory Medicine,
University Hospital Regensburg. After sterile density gradient cen-
trifugation lymphocytes were counted and re-suspended at cell
densities of 5–10× 106/ml in fetal-calf serum (FCS)-free, GMP
grade culture medium. For the dose escalation part, PBLs of the
patients were frozen in aliquots. After simultaneous addition of
Hsp70 peptide TKD (2µg/ml, Bachem) and recombinant IL-2
(100 IU/ml Aldesleukine, Chiron) the cell suspensions were trans-
ferred into 250 ml Teflon culture bags (VueLife-118) and incubated
in an incubator at 37°C for 3–5 days under gentle rotation. After
washing in physiological saline (0.9% NaCl) and harvesting, the
cells were suspended in physiological saline (500 ml) conditioned
with 100 IU/ml recombinant IL-2. Sterility testing of the cell prod-
ucts was performed before, on day 3 and directly before re-infusion
of the cells (Figure 1). Four of the 12 patients who were treated
within an intra-individual and inter-individual dose escalation
schedule showed no adverse effects. Therefore, from patient 4
onward all patients received the complete leukapheresis product
containing between 0.7× 109 and 8.5× 109 PBLs in a single injec-
tion. The number of activated NK cells, which were re-infused
ranged from 0.1× 109 to 1.5× 109 cells in all patients. These treat-
ments were repeated up to six times in individual patients without
observing any toxic side effects. The laboratory parameters, which
were taken before and after each re-infusion cycle showed no NK
cell-based treatment associated changes. A gradual deterioration
of bilirubin, lactate dehydrogenase, and liver enzymes in some
patients could be related to the disease progression. Irrespectively
FIGURE 1 | Scheme of the NK cell activation in the clinical phase I trial.
NSCLC patients after radiochemotherapy undergo leukapheresis and the
immune phenotype (NK cell and T cell markers) is assessed by flow
cytometry. Following erythrocyte depletion on a SEPAX system peripheral
blood lymphocytes (PBLs) are stimulated ex vivo in a GMP laboratory with
TKD/IL-2 for 3–5 days. After measuring of NK activation markers and sterility
testing, the activated cells are washed and re-infused (i.v.) in the patient.
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of the treatment cycle, the number of leukocytes, thrombocytes,
and hemoglobin remained unaltered at each leukapheresis. After
each re-infusion, vital parameters of all patients were monitored
for at least 1 h. Only after the first re-infusion of the cells into
the first patient, the patient was hospitalized overnight. A graphic
overview of the NK cell activation process is shown in Figure 1. In
step 1, patient received a leukapheresis, after gradient density cen-
trifugation, patient-derived PBLs were tested for their activity by
flow cytometry and functional assays. Then PBLs were incubated
with TKD/IL-2 for 3–5 days in a GMP laboratory. After testing
viability, sterility, and functional characteristics, cells were washed
twice in 0.9% NaCl solution. Then activated cells were re-infused
in 500 ml 0.9% NaCl conditioned with IL-2 (100 IU/ml) into the
patient by i.v. injection within 30–60 min.
In addition to routine laboratory exams also specific laboratory
parameters were determined from the blood product and from
the patient before treatment, before leukapheresis, before cell re-
infusion, and after cell re-infusion. The immune phenotype of the
lymphocytes and the release of cytokines such as IFNγ, TNFα,
and the apoptosis-inducing enzyme granzyme B were determined
in the ex vivo cell culture before and after stimulation and in the
blood of the patient before and after re-infusion of the activated
cells. From day 1 to 4 of stimulation, the expression density of
CD94 on activated NK cells continuously increased as it has been
shown for healthy individuals previously. A comparison of the
mean fluorescence intensity of the Hsp70 receptor CD94 after
the first and the fourth treatment cycle also revealed a significant
increase. These data indicate that similar to healthy controls the
CD94 expression could also be increased on NK cells of tumor
patients that had been treated with radio- and/or chemotherapy
before. With respect to the cytolytic activity of ex vivo stimulated
NK cells, 10 out of the 12 patients showed a significant increase
after stimulation with Hsp70 peptide plus IL-2. In contrast, a stim-
ulation of the patient’s cells with IL-2 alone showed no significant
increase in the cytolytic activity. Studies using either Hsp70 spe-
cific or CD94 specific antibodies to block the target structure or
the NK receptor demonstrated that Hsp70 is recognized on tumor
cells by CD94-positive NK cells of the patients. Most interestingly,
we could show that the cytolytic activity of ex vivo stimulated NK
cells could be confirmed in the blood of the patients even 24 h after
re-infusion of the cells. A comparison of the activity of NK cells in
the blood before and after the fourth re-infusion cycle revealed sig-
nificantly increased cytolytic responses of the blood lymphocytes
in three out of five patients.
Clinical tumor responses (one stable disease, one mixed
response) could be observed in one patient with colorectal and
one patient with NSCLC who received at least four treatment
cycles (29). Despite the low numbers, these findings were not
expected due to the fact that all patients suffered from advanced
tumor stages and had progressive disease during their last standard
therapy.
In summary, the phase I clinical trial showed that re-infusion
of Hsp70 peptide TKD plus IL-2 activated autologous NK cells
is feasible, safe, and well tolerated. The immunological and
clinical responses warrant additional studies in patients with a
lower tumor burden and a confirmed mHsp70-positive tumor
phenotype (29).
DESCRIPTION OF AN ONGOING PROOF-OF-CONCEPT CLINICAL PHASE
II TRIAL USING Hsp70 PEPTIDE PLUS IL-2 ACTIVATED NK CELLS IN
PATIENTS WITH NSCLC FOLLOWING RADIOCHEMOTHERAPY
There is still a strong need to further improve the therapy
of patients with non-resectable locally advanced NSCLC, since
despite multimodal therapies the prognosis of those patients
remains bad with a median OS of approximately 16 months.
In this tumor stage, <20% of the patients survive more than
5 years (30). Several approaches to improve outcome have been
evaluated, including systemic treatments or novel radiation tech-
niques. The addition of chemotherapy did not enhance OS
in these patients significantly (31). Although a distinct dose–
response relationship is known for radiation therapy in lung
cancer, escalated regimes have not improved outcome in NSCLC
as shown in a prospective clinical trial (32). Immunotherapy
seems to be a promising concept to improve the therapy of
those patients. Since the membrane expression density of Hsp70
could be selectively enhanced on tumor cells following stan-
dard therapies such as ionizing irradiation and chemotherapy
in vitro, we aimed to treat tumor patients with Hsp70 peptide
TKD plus IL-2 activated (TKD/IL-2) autologous NK cells that
had been treated with a RCTx. On the one hand, RCT should
reduce the actual mass of viable tumor cells, and on the other
hand, RCT should enhance the membrane density of Hsp70,
which is recognized by pre-activated NK cells. Patients (n= 90)
with NSCLC in non-metastasized but locally advanced stages
IIIA and IIIB after RCTx (platinum based chemotherapy, 60–
70 Gy) will be enrolled into the randomized multicenter clinical
phase II trial (EUDRA-CT:2008-002130-30). Previous findings
have indicated that a mHsp70-positive tumor phenotype is asso-
ciated with a significantly decreased OS (16). Therefore, this
interventional phase II trial incorporates a 1:1 randomized con-
trol group of patients that receive no adjuvant NK cell-based
immunotherapy in addition to the current standard of treat-
ment (simultaneous RCTx), and also exhibit a mHsp70-positive
tumor phenotype.
The major in- and exclusion criteria of the trial are summa-
rized in Table 1. The scheme of the ongoing clinical phase II trial
is shown in Figure 2. In a pre-study part, the Hsp70 phenotype
of the tumor will be assessed in the blood of the patient by an
Hsp70-specific ELISA and if available on tumor biopsies by flow
cytometry using an Hsp70-specific mouse monoclonal antibody
and the tumor stage will be determined. After successful RCTx
(partial response, or at least stable disease) NSCLC patients in
stage IIIA and IIIB will be randomized into the study. Patients in
the interventional study arm receive four cycles of ex vivo TKD/IL-
2 stimulated NK cells on a monthly schedule. Tumor assessment
will be performed in both arms of the trial every 3 months for
the first year and every 6-month thereafter until progression of
disease.
The mHsp70 status on the tumor will be assessed in a pre-study
screening part carried out in the Department of Experimen-
tal Radiation Oncology at the Klinikum rechts der Isar, Tech-
nische Universität München (TUM). Tumor biopsies obtained
during the bronchoscopy at primary staging will be sent to the
sponsor’s laboratory. Freshly isolated single cell suspensions of
biopsies are used for analysis of the Hsp70 tumor phenotype.
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Table 1 | In- and exclusion criteria of the ongoing phase II clinical trial: targeted NK cell-based adoptive immunotherapy for the treatment of
patients with non-small cell lung cancer (NSCLC) after radiochemotherapy.
Inclusion criteria Exclusion criteria
First diagnose of histologically and/or cytologically proven and
unresectable NSCLC with clinical stage III A and III B
Prior treatment with any other investigational drug within 4 weeks prior to first dose
of study medication
Completion of radiochemotherapy no longer than 8 weeks ago Any severe heart disease or any severe concomitant disease (ECOG status >2)
Progression free according to RECIST 1.1 criteria at the first
assessment after completion of radiochemotherapy
NSCLC patients (stage IIIA/B) eligible for initial surgery with a confirmed consent of
an interdisciplinary tumor board
Confirmed presence of Hsp70 on the patient’s tumor Patients that show ALK positivity or an activating mutation of the EGFR-TK domain
(assessment of ALK or EGFR status not mandatory)
Female or male, age 18–75 years Patients with locally advanced or metastatic NSCLC other than predominantly
squamous cell histology
ECOG status ≤2 Any disease (including psychotic disorders, drug abuse, active infection,
uncontrolled hypertension, unstable angina, congestive heart failure, myocardial
infarction within the previous year, serious cardiac arrhythmia requiring medication,
hepatic, renal or metabolic disease), metabolic dysfunction, physical examination
finding, or clinical laboratory finding like (in the investigator’s opinion) to affect the
evaluation of the study or place the patient at risk whilst on treatment
Neutrophil count ≥1.5×109/l after completion of
radiochemotherapy
Any serious infection or sepsis
White blood cell (WBC) ≥2.5×109/l after completion of
radiochemotherapy
Any active autoimmune disease
Hemoglobin ≥8 g/l after completion of radiochemotherapy Any immunodeficiency syndrome
Platelet count ≥100×109/l after completion of radiochemotherapy Surgery or immunotherapy within 4 weeks before study entry
Normal renal function (creatinine <150% ULN) Patients with a known hypersensitivity to any of the administered substances
should be excluded from the clinical trial
Normal liver function (bilirubin <150% ULN; G-GT, GPT and GOT
<250% ULN)
Patients with a known positive HIV test should be excluded from the clinical trial as
well as patients with positive hepatitis A, B, C tests (assessment not mandatory)
Normal blood coagulation (PTT 25–40 s) Receipt of immunosuppressive drugs including systemic corticosteroids within
3 weeks before study entry. Low dose corticosteroids as they are a common
treatment option for patients suffering from COPD are not an exclusion criteria
Measurable disease according to immune related RECIST criteria Radio- cytostatic- and immunotherapy in parallel or within 2 weeks prior study start
Female patients of childbearing potential must have negative
pregnancy test performed during screening period (≤14 days
before initiation of study dosing)
Women who are pregnant or breast feeding
Postmenopausal women must be amenorrheal for at least
12 months to be considered of non-childbearing potential. Female
patients of reproductive potential must agree to employ an
effective method of birth control throughout the study and for
6 months following discontinuation of study drug
Female patients of reproductive potential unwilling to practice a highly effective
method of birth control
Written (signed) informed consent document indicating that the
patient of all pertinent aspects of the trial prior to enrollment and
to participate in the study
History of non-compliance with medical regimes
Ability to comply with the study Patients unwilling to or unable to comply with the protocol
If bronchoscopy has been performed alio loco prior to patient
admittance, the mHsp70 expression will be determined by quanti-
fying the amount of exosomal Hsp70 in the blood of the patients.
Previously, we have shown that mHsp70-positive tumor cells
actively release Hsp70 in exosomes, which present Hsp70 on their
surfaces. Since most commercial Hsp70 ELISAs are unable to
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FIGURE 2 | Scheme of the phase II clinical trial. In the pre-study part, the
Hsp70 phenotype and the stage of the tumor disease is assessed. Only
Hsp70-positive NSCLC patients in stage IIIA/B who received a
radiochemotherapy (RCTx) and showed at least a stable disease are
randomized into the trial. The interventional group receives four cycles of ex
vivo TKD/IL-2 activated NK cells on a monthly basis; the control group gets
best supportive care. Tumors will be assessed in the first year every
2–3 months by CT in both groups.
detect lipid-bound, exosomal Hsp70 in the serum we established
a novel lipHsp70 ELISA test. This ELISA detects and quantifies
exosomal Hsp70 in the serum of patients with a high accu-
racy (patent filed). Using this Hsp70 ELISA, we could show
that patients with tumors of different entities (including NSCLC
patients) exhibit significantly higher Hsp70 serum levels than
a group of age- and gender-matched healthy volunteers (33).
Therefore, in the screening part of the study, Hsp70 serum lev-
els will be measured in NSCLC patients before and after RCTx.
In the therapeutic clinical phase II trial, Hsp70 serum levels will
be assessed before and after NK cell-based immunotherapy for
the treatment group and at identical fixed time points for the
control group. The mHsp70 phenotype will be correlated with
the Hsp70 serum levels and the tumor volume will be corre-
lated with the Hsp70 serum level. Furthermore, the results of the
Hsp70 serum values before and after therapy will help to eluci-
date, whether serum Hsp70 levels can improve the monitoring
of the clinical outcome after therapeutic intervention. The results
of the Hsp70 serum levels will also help to further validate the
role of exosomal Hsp70 as a prognostic/diagnostic tumor bio-
marker, as it was suggested for head and neck, lung, colorectal,
pancreatic, brain cancer, and leukemic patients before (33). Ele-
vated levels of Hsp70 in the serum were also found in patients
with squamous cell carcinoma of the head and neck (34) and
glioblastomas (35).
Identical to the phase I clinical trial the leukapheresis prod-
ucts, which are used as source material for stimulated NK cells, are
produced centralized at the Institute for Clinical Chemistry and
Laboratory Medicine, Transfusion Medicine, University Hospital
Regensburg, under GMP conditions in order to obtain comparable
cell products. Afterwards cell processing is performed in a GMP
cleanroom laboratory. For all manufacturing steps, the permis-
sion of the competent authorities was obtained. NSCLC patients
in the treatment arm will be treated four times every 2–6 weeks
with ex vivo TKD/IL-2 stimulated NK cells after RCTx. In case of
significant toxicities, the treatment will be interrupted, the dose of
re-infused cells will either be reduced or stopped. Patients in the
control arm also have received standard RCTx prior to enrollment.
Tumor assessment will be done for both study groups at enroll-
ment, every 3 months during the first year and every 6-month
thereafter until progression of disease. Response to treatment will
be assessed centrally at TU München in order to prevent bias.
REGULATORY ASPECTS AND PRODUCTION OF THE INVESTIGATIONAL
MEDICINAL PRODUCT OF THE PHASE II CLINICAL TRIAL (APCETH GmbH
UND Co. KG, MUNICH)
The Investigational Medicinal Product (IMP) is classified as an
advanced therapy medicinal product [ATMP, somatic cell product,
Regulation (EC) No 1394/2007]. The process established in an aca-
demic institution for the phase I had to be transferred and adapted
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to the actual requirements for ATMP’s. The process required
approximately 1.5 years and was completed with the manufacturer
license granted to apceth by the local and national authority as a
prerequisite for the clinical trial application by the sponsor. The
manufacturing of TKD-activated autologous NK cells follows the
principles of good-manufacturing practice (EU-GMP guidelines)
in order to provide a robust and reproducible pharmaceutical
product.
The implementation involved the development phase, the
transfer to GMP, and the implementation of a GMP-compliant
process. The development phase defined the process steps (closed
systems wherever possible), the equipment and quality control
(QC) methods, the definition of in-process controls, and the mate-
rials (should be available in adequate quality). The comparability
to the process applied for phase I and the results obtained should
be confirmed. The transfer phase involved a stepwise implemen-
tation to full GMP mainly relating to up-scaling from small-scale
(microtiter-plates), medium-scale (bags with small volume of cell
suspension), and large-scale in addition to the qualification of the
materials and analytical methods. The GMP-process was estab-
lished with the successful validation of the QC methods and the
validation of the process by media-fills and qualification runs.
The modifications to the phase I process relate to the exact spec-
ification of the starting material “apheresis product” including
transport to the GMP-facility, the introduction of closed systems
(density centrifugation of the starting material is now performed
in a Sepax® device and harvesting/washing procedures in closed
systems; in a class B room), release criteria, and test methods.
Special attention was paid to the reconstitution buffer [Ringer-
lactate and 0.1% human serum albumin (HAS)] and the shelf-life
(24 h) as the end product is delivered to several study centers.
Most of the development work was attributed to the definition
and validation of analytical QC methods (flow cytometry) and
the qualification of ancillary and raw materials (for example, TKD
and cytokines). Flow cytometry of the activated NK cell popula-
tion was challenging and different approaches had to be evaluated
resulting in a change of specification (CD94) and the introduction
of a parallel culture for QC-testing to test for the mean fluores-
cence intensity. The test results according to the specifications
for potency, purity, identity, and absence of microbial contami-
nation/endotoxins/mycoplasma are the basis for the release of the
final product for further application by the qualified person. This
IMP is not cryo-preserved and has a limited shelf-life; at least the
sterility results are not available at the time of application and
requiring a well-defined aseptic manufacturing process.
The seven participating study sites have been initiated in 2014
and the study will last for approximately 2 years after the inclu-
sion of the first patient (in 2015) into the interventional study
part. Since the phase I trial (29) and pilot studies (36) have shown
that four repeated infusion cycles of ex vivo stimulated, autolo-
gous leukapheresis products lead to elevated basal NK cell activity
in the peripheral blood of the patients, four treatment cycles will
also be administered in the clinical phase II trial. The NK cell
activity in the peripheral blood of the patients will be determined
prior to study entry and start of adjuvant immunotherapy, every
3 months after enrollment for the first year and every 6-month
thereafter to determine the biological activity. Multiparameter
Table 2 | Panel of CE-certified, fluorescence-labeled antibodies
(Beckman Coulter), which are used in the clinical trial.
Fluorescence-conjugated
antibodies
Article# Specificity
IgG1-FITC/PE/PC7/APC A07795/A07796 Control
737662/IM2475
IgG2a-PE/APC A09142/A12693 Control
CD3-FITC−/CD94-APC+ A07746/B09980 NK cells
CD3-FITC−/CD56-PE+ A07746/A0788 NK cells
CD3-FITC−/CD16-PE+ A07746/A07766 NK cells
CD3-FITC+/CD56-PE− A07746/A0788 NKT cells
CD3-PC7+ 737657 T cells
CD3-PC7+/CD4-PE+ 737657/A07751 T helper cells
CD3-PC7+/CD8-APC+ 737657/IM2469 T cytotoxic cells
CD3-FITC−/CD19-PC7+ A07746/IM3628 B cells
CD3-FITC−/CD14-PE A07746/A07764 Macrophages
CD45-APC+ A79392 Leukocytes
CD66b(CD67)-FITC+ IMO531-U Neutrophils, eosinophils,
granulocytes
7-AAD (A07704) was used as a viability dye.
flow cytometric analysis will be performed with the peripheral
blood of the patients to determine the activation status of the
NK and T cells using a pre-fixed panel of antibodies as indi-
cated in Table 2. The cytotoxic response of patient derived NK
cells before and after RCTx and after immunotherapy will be
assessed by Europium cytotoxicity assays using K562 cells as a
classical NK cell target and by measuring the density of NK/T
cell activation markers such as CD94 and CD69 in the labo-
ratory of Gabriele Multhoff at the TUM. Serum Hsp70 levels
will be measured as mentioned above. In parallel to the blood
analysis, tumor response assessment will be performed and cen-
trally reviewed according to the immune related Response Criteria
(irRC). Patients will be excluded when they show progressive dis-
ease according to irRC [increase of tumor burden more than 25%
relative to nadir (minimum recorded tumor burden, confirmation
by a repeat, consecutive assessment no <4 weeks from the date first
documented)].
CONCLUDING REMARKS
This review aims to summarize results from bench to bedside
experiments that resulted in the initiation of a phase II clinical
trial using ex vivo activated NK cells in a targeted immunother-
apy of NSCLC patients after RCTx bearing Hsp70 membrane-
positive tumors. Hsp70 has been found to serve as a biomarker
for highly aggressive tumors and metastases (5, 6, 19). Preclinical
data have shown that stimulation of NK cells with Hsp70 pep-
tide TKD plus IL-2 results in an increased migratory capacity of
NK cells and an enhanced killing of Hsp70 membrane-positive
tumor cells in vitro (24), and in relevant tumor mouse models
(28). An increased expression density of the C-type lectin receptor
CD94 has been identified as a useful surrogate for the cytolytic
www.frontiersin.org April 2015 | Volume 6 | Article 162 | 7
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Specht et al. Hsp70-based immunotherapy after radiochemotherapy in NSCLC patients
activity of NK cells (25, 26), and granzyme B-mediated apop-
tosis was found to be responsible for the killing of tumor cells
presenting Hsp70 on their cell surface (27). A phase I clinical
trial has shown that re-infusion of ex vivo TKD/IL-2 stimulated
autologous NK cells in patients with late-stage colorectal cancers
and NSCLC is feasible, safe, and well tolerated (29). As stress,
such as RCTx has been found to increase the cell surface den-
sity of Hsp70 selectively on tumor cells (21), a proof-of-concept
phase II clinical trial was initiated in NSCLC patients stage IIIA/B
after RCTx.
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